Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.C. Kessler, W.T. Chiu, O. Demler, E.E. Walters.
Prevalence, severity and comorbidity of twelve month DSM IV disorders in the National Comorbidity Survey Replication.
Arch Gen Psychiatry, 62 (2005), pp. 617-627
[2.]
J. Alonso, M.C. Angermeyer, J.P. Lepine.
El estudio europeo de la epidemiología de de los trastornos mentales (ESEMeD) del proyecto.
Acta Psychiatr Scand, 420 (2004), pp. 5-7
[3.]
K.B. Wells, A. Stewart, R.D. Hays, M.A. Burnam, W. Rogers, M. Daniels, et al.
The functioning and well-being of depressed patients: results from the medical outcomes study.
JAMA, 262 (1989), pp. 914-919
[4.]
J.J. Schildkraut.
The catecholamine hypothesis of affective disorders: a review of supporting evidence.
Am J Psychiatry, 122 (1965), pp. 509-522
[5.]
T.A. Wehr, A. Wirz-Justice.
Circadian rhythm mechanisms in affective illness and in antidepressant drug action.
Pharmacopsychiatria, 15 (1982), pp. 31-39
[6.]
D.B. Boivin.
Influencia de sueño-vigilia y alteraciones del ritmo circadiano en trastornos psiquiátricos.
J Psychiatry Neurosci, 35 (2000), pp. 446-458
[7.]
A. Wirz-Justice.
Biological rhythm disturbances in mood disorders.
Int Clin Psychopharmacol, 21 (2006), pp. 11-15
[8.]
R.Y. Moore.
Circadian rhythms: basic neurobiology and clinical applications.
Annu Rev Med, 48 (1997), pp. 253-266
[9.]
G.C. Brainard, J.P. Hanifin, J.M. Greeson, B. Byrne, G. Glickman, E. Gerner, et al.
Espectro de acción para la regulación de melatonina en los humanos: las pruebas de un fotorreceptor circadiano novela.
J Neurosci, 21 (2002), pp. 6405-6412
[10.]
M.M. Macchi, J.N. Bruce.
Human pineal physiology and functional significance of melatonin.
Front Neuroendocrinol, 25 (2004), pp. 177-195
[11.]
S.R. Pandi-Perumal, V. Srinivasan, G.J.M. Maestroni, D.P. Cardinali, B. Poeggeler, R. Hardeland.
Melatonin: nature's most versatile biological signal?.
FEBS J, 273 (2006), pp. 2813-2838
[12.]
S. Hattar, R.J. Lucas, N. Mrosovsky, S. Thompson, R.H. Douglas, M.W. Hankins, et al.
Melanopsin and rod-cone photoreceptive systems account for all major accessory visual functions in mice.
Nature, 424 (2003), pp. 76-81
[13.]
S.R. Pandi-Perumal, V. Srinivasan, D.W. Spence, D.P. Cardinali.
Role of melatonin system in the control of sleep.
CNS Drugs, 21 (2007), pp. 995-1018
[14.]
F.W. Turek.
From circadian rhythms to clock genes in depression.
Int Clin Psychopharmacol, 22 (2007), pp. S1-S8
[15.]
T. Tsujimoto, N. Yamada, K. Shimoda, K. Kanada, S. Takahashi.
Circadian rhythms in depression. Part II: circadian rhythms in inpatients with various mental disorders.
J Affect Disord, 18 (1990), pp. 199-210
[16.]
E. Van Cauter, R. Leproult, D.J. Kupfer.
Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol.
J Clin Endocrinol Metab, 81 (1996), pp. 2468-2473
[17.]
B. Claustrat, G. Chazot, J. Brun, D. Jordan, G. Sassolas.
Un cronobiológico estudio de la melatonina y la secreción de cortisol en pacientes depresivos: plasma la melatonina, un marcador bioquímico en la depresión mayor.
Biol Psychiatry, 19 (1984), pp. 1215-1228
[18.]
C. Paccierotti, S. Iapichino, L. Bossini, F. Pieraccini, P. Castrogiovanni.
Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry.
Front Neuroendocrinol, 22 (2001), pp. 18-32
[19.]
M. Crasson, S. Kjiri, A. Colin, K. Kriri, M. L’Hermite-Baleriaux, M. Ansseau, et al.
Serum melatonin and urinary 6-sulphatoxy-melatonin in major depression.
Psychoneuroendocrinology, 29 (2004), pp. 1-12
[20.]
E. Palazidou, A. Papadopoulos, H. Ratcliff, S. Dawling, S.A. Checkley.
Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients.
Psychol Med, 22 (1992), pp. 309-315
[21.]
L.A. Carvalho, C. Gorenstein, R.A. Moreno, R.P. Markus.
Melatonin levels in drug-free patients with major depression from the southern hemisphere.
Psychoneuroendocrinology, 31 (2006), pp. 761-768
[22.]
E.J. Dalton, D. Rotondi, R.D. Levitan, S.H. Kennedy, G.M. Brown.
Use of slow-release melatonin in treatment-resistant depression.
J Psychiatry Neurosci, 25 (2000), pp. 48-52
[23.]
M.J. Millan, A. Gobert, F. Lejeune, A. Dekeyne, A. Newman-Tancredi, V. Pasteau, et al.
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
J Pharmacol Exp Ther, 306 (2003), pp. 954-964
[24.]
P. Delagrange, J.A. Boutin.
Therapeutic potential of melatonin ligands.
Chronobiol Int, 23 (2006), pp. 413-418
[25.]
M. Papp, P. Gruca, P.A. Boyer, E. Mocaer.
Effect of agomelatine in the chronic mild stress model of depression in the rat.
Neuropsychopharmacology, 28 (2003), pp. 694-703
[26.]
W.J. Riedel, T. Klaassen, E. Griez, A. Honig, P.P.C.A. Menheere, H.M. Van Praag.
Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood.
Neuropsychopharmacology, 26 (2002), pp. 358-367
[27.]
M.I. Masana, S. Benloucif, M.L. Dubocovich.
Circadian rhythm of MT1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse.
J Pineal Res, 28 (2000), pp. 185-192
[28.]
M.C. Holmes, K.L. French, J.R. Seckl.
Dysregulation of diurnal rhythms of serotonin 5-HT2C and corticosteroid receptor gene expression in the hippocampus with food restriction and glucocorticoids.
J Neurosci, 17 (1997), pp. 4056-4065
[29.]
D.J. Kennaway, R.W. Moyer, A. Voultsios, T.J. Varcoe.
Serotonin, excitatory aminoacids and the photic control of melatonin rhythms and SCN c-FOS in the rat.
Brain Res, 897 (2001), pp. 36-43
[30.]
D.J. Kennaway, R.W. Moyer.
Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms.
Brain Res, 806 (1998), pp. 257-270
[31.]
M. Zupancic, C. Guilleminault.
Agomelatine: a preliminary review of a new antidepressant.
CNS Drugs, 20 (2006), pp. 981-992
[32.]
M.L. Dubocovich.
Drug evaluation: agomelatine targets a range of major depressive disorder symptoms.
Curr Opin Investig Drugs, 7 (2006), pp. 670-680
[33.]
N. Hanoun, E. Mocaer, P.A. Boyer, M. Hamon, L. Lanfumey.
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain.
Neuropharmacology, 47 (2004), pp. 515-526
[34.]
R. Leproult, A. Van Onderbergen, M. L’Hermite-Baleriaux, E. Van Cauter, G. Copinschi.
Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.
Clin Endocrinol, 63 (2005), pp. 298-304
[35.]
T.J. Varcoe, D.J. Kennaway, A. Voultsios.
Activation of 5-HT2C receptors acutely induces per gene expression in the rat suprachiasmatic nucleus at night.
Brain Res Mol Brain Res, 119 (2003), pp. 192-200
[36.]
I. Gurevich, H. Tamir, V. Arango, A.J. Dwork, J.J. Mann, C. Schmauss.
Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims.
Neuron, 34 (2002), pp. 349-356
[37.]
J. Yamada, Y. Sugimoto.
Effects of 5-HT2 receptor antagonists on the antiimmobility effects of imipramine in the forced swimming test with mice.
Eur J Pharmacol, 427 (2001), pp. 221-225
[38.]
H. Lôo, A. Hale, H. D’Haenen.
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placeboecontrolled dose range study.
Int Clin Psychopharmacol, 17 (2002), pp. 239-247
[39.]
S. Kennedy, R.A. Emsley.
Placeboecontrolled trial of agomelatine in the treatment of major depressive disorder.
Eur Neuropsychopharmacol, 16 (2006), pp. 93-100
[40.]
J.P. Olié, S. Kasper.
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Int J Neuropsychopharmacol, 10 (2007), pp. 661-673
[41.]
S.A. Montgomery, S. Kasper.
Severe depression and antidepressants: focus on a pooled analysis of placeboecontrolled studies on agomelatine.
Int Clin Psychopharmacol, 22 (2007), pp. 283-291
[42.]
J.R. Calabrese, J.D. Guelfi, C. Perdrizet-Chevallier, Agomelatine bipolar study group.
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data.
Bipolar Disord, 9 (2007), pp. 628-635
[43.]
S.A. Montgomery, S.H. Kennedy, G.D. Burrows, M. Lejoyeux, I. Hindmarch.
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation with paroxetine: a randomized, double-blind, placebo controlled discontinuation study.
Int Clin Psychopharmacol, 19 (2004), pp. 271-280
[44.]
R.M. Benca, W.H. Obermeyer, R.A. Thisted, J.C. Gillin.
El sueño y psiquiátricos trastornos. Un meta-análisis.
Arch Gen Psychiatry, 49 (1992), pp. 651-668
[45.]
M.G. Cole, N. Dendukuri.
Risk factors for depression among elderly community subjects: a systematic review and meta-analysis.
Am J Psychiatry, 160 (2003), pp. 1147-1156
[46.]
D. Riemann, M. Berger, U. Vodelholzer.
Sleep and depression; results from psychobiological studies: an overview.
Biol Psychol, 57 (2001), pp. 67-103
[47.]
C. Cajochen, K. Krauchi, D. Mori, P. Graw, A. Wirz-Justice.
Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis.
Am J Physiol, 272 (1997), pp. R1189-R1196
[48.]
M.C. Lopes, M.A. Quera-Salva, C. Guilleminault.
Cyclic alternating pattern in the nREM sleep of patients with major depressive disorder: baseline results and change overtime with a new antidepressant: agomelatine.
Sleep Med, 6 (2005), pp. 87-88
[49.]
M.A. Quera-Salva, B. Vanier, J. Laredo, S. Hartley, F. Chapopot, C. Moulin, et al.
Major depressive disorder, sleep EEG and agomelatine: an open-label study.
Int J Neuropsychopharmacol, 10 (2007), pp. 691-696
[50.]
G.M. Goodwin.
Clinical Studies on the efficacy of agomelatine on depressive symptoms.
CNS Drugs, 23 (2009), pp. 35-39
[51.]
S.H. Kennedy.
Agomelatine. Efficacy at each phase of antidepressant treatment.
CNS Drugs, 23 (2009), pp. 41-47
[52.]
M. Bourin, C. Prica.
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depresión.
Curr Pharmaceutical Design, 15 (2009), pp. 1675-1682
[53.]
Y. Agid, G. Buzsaki, D.M. Diamond, R. Frackowiak, J. Giedd, J.A. Girault, et al.
How can drug discovery for psychiatric disorders be improved?.
Nat Rev Drug Discov, 6 (2007), pp. 189-201
[54.]
S.H. Kennedy.
A double blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
J Clin Psychopharmacol, 28 (2008), pp. 329-333
Copyright © 2010. Sociedad Española de Psiquiatría and Sociedad Española de Psiquiatría Biológica